An observational study in Atrial Fibrillation, sponsored by Boehringer Ingelheim. Completed at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-04.
Sponsored by Boehringer Ingelheim · Observational
This is a retrospective, observational, claims cohort study to assess, for adult patients initiating an oral anticoagulant for NVAF
This is a retrospective, observational, claims cohort study to assess, for adult patients initiating an oral anticoagulant for NVAF, the incidence rates of emergency surgery, major bleeding due to trauma, and major bleeding due to fracture, overall and stratified by age (\<64, 65-74, >75). The secondary objective is to estimate the overall and age stratified incidence of cardiac tamponade and peri-cardiocentesis.
Any patients with atrial fibrillation contained in the Medical Data Vision (MDV) database which is a Japanese, nationwide claims data containing approximately 16 million patients cumulatively. The data cut is between March 2011 to June 2016, and the patients in the MDV database are those who have visited DPC hospitals (diagnostic procedure combination, a lump-sum payment system based on disease diagnosis to be treated similar to Medicare/Medicaid in the USA) hospitals which provide acute in-patient, as well as outpatient care.
->18 year old non-valvular atrial fibrillation (NVAF) patients
Exclusion Criteria:
warfarin and non-vitamin K dependent oral anti-coagulants
Drug: warfarin · Drug: dabigatran · Drug: Apixaban · Drug: Edoxaban · Drug: Rivaroxaban
warfarin
Non-vitamin K dependent oral anti-coagulants (NOACs)
Also known as: PRADAXA, PRAZAXA
Non-vitamin K dependent oral anti-coagulants (NOACs)
Non-vitamin K dependent oral anti-coagulants (NOACs)
Non-vitamin K dependent oral anti-coagulants (NOACs)
The Number of Patients With Emergency Surgery and Major Bleeding Due to Fracture or Trauma.
The number of patients with emergency surgery and major bleeding due to fracture or trauma. Where emergency surgery defined as any surgical procedure (International Classification of Diseases (ICD) 10 code K000-879) performed on the same day as hospital admission with additional claims, major bleeding due to fracture is any bleeding associated with hospitalization or blood transfusion (ICD10 code E83.111) accompanied by any fracture, and major bleeding due to trauma is any bleeding associated with hospitalization or blood transfusion (ICD10 code E83.111) accompanied by any trauma.
Time frame: One year
The Number of Patients With Cardiac Tamponade and Pericardiocentesis.
The number of patients with cardiac tamponade and pericardiocentesis. Cardiac tamponade diagnosis (ICD 10 code 4200001) on the same or next day as catheter ablation or percutaneous coronary intervention (PCI), Pericardiocentesis (Medical Data Vision (MDV) procedure code 140010510) on the same or next day as catheter ablation or PCI.
Time frame: One year
Non-interventional study based on existing health insurance claims data
| Milestone | Patients Prescribed With Non-warfarin Oral Anti Coagulants |
|---|---|
| Started | 53969 |
| Completed | 53969 |
| Not completed | 0 |
The number of patients with emergency surgery and major bleeding due to fracture or trauma. Where emergency surgery defined as any surgical procedure (International Classification of Diseases (ICD) 10 code K000-879) performed on the same day as hospital admission with additional claims, major bleeding due to fracture is any bleeding associated with hospitalization or blood transfusion (ICD10 code E83.111) accompanied by any fracture, and major bleeding due to trauma is any bleeding associated with hospitalization or blood transfusion (ICD10 code E83.111) accompanied by any trauma.
| Number of Patients | Patients Prescribed With Non-warfarin Oral Anti Coagulants |
|---|---|
| Age <=64 | 14 |
| Age 65-74 | 35 |
| Age >=75 | 84 |
The number of patients with cardiac tamponade and pericardiocentesis. Cardiac tamponade diagnosis (ICD 10 code 4200001) on the same or next day as catheter ablation or percutaneous coronary intervention (PCI), Pericardiocentesis (Medical Data Vision (MDV) procedure code 140010510) on the same or next day as catheter ablation or PCI.
| Number of Patients | Patients Prescribed With Non-warfarin Oral Anti Coagulants |
|---|---|
| The Number of Patients With Cardiac Tamponade and Pericardiocentesis. | 1 |
Collected over No adverse event reporting was done.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Patients Prescribed With Non-warfarin Oral Anti Coagulants | — | — | — |
Baseline characteristics are based on the number of patients meeting the inclusion and exclusion criteria.
| Age, Continuous(Years) | Patients Prescribed With Non-warfarin Oral Anti Coagulants |
|---|---|
| Mean | 76 ± 10 |
| Sex: Female, Male(Participants) | Patients Prescribed With Non-warfarin Oral Anti Coagulants |
|---|---|
| Female | 21587 |
| Male | 32382 |
| Ethnicity (NIH/OMB)(Participants) | Patients Prescribed With Non-warfarin Oral Anti Coagulants |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 53969 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Patients Prescribed With Non-warfarin Oral Anti Coagulants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 53969 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: Undecided
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boehringer Ingelheim